ortho-Lithiophenyl Isocyanide: A Versatile Precursor for 3*H*-Quinazolin-4-ones and 3*H*-Quinazolin-4-thiones

LETTERS 2009 Vol. 11, No. 2 389-392

ORGANIC

Alexander V. Lygin and Armin de Meijere*

Institut für Organische und Biomolekulare Chemie der Georg-August-Universität Göttingen, Tammannstrasse 2, D-37077 Göttingen, Germany

ameijer1@gwdg.de

Received November 18, 2008



ortho-Lithiophenyl isocyanide has been generated from ortho-bromophenyl isocyanide and successfully employed toward the synthesis of 2-substituted phenyl isocyanides as well as 2,3-disubstituted 3*H*-quinazoline-4-ones and 3*H*-quinazolin-4-thiones.

Isocyanides have found a wide range of applications in organic synthesis,¹ particularly in the synthesis of heterocycles.² The electron-withdrawing effect of the isocyano group enhances the acidity of α -C,H bonds, and this was

(1) For reviews, see: (a) Ito, Y. Science of Synthesis; Suginome, S.-I.,; Murahashi, M., Eds.; Thieme, Stuttgart, 2004; Vol. 19, pp 445–530. (b) For recent reviews on multicomponent reactions with isocyanides, see:(c) Bienayme, H.; Hulme, C.; Oddon, G.; Schmitt, P. Chem.-Eur. J. 2000, 6, 3321–3329. (d) Zhu, J. Eur. J. Org. Chem. 2003, 1133–1144. (e) Nair, V.; Rajesh, C.; Vinod, A. U.; Bindu, S.; Sreekanth, A. R.; Mathen, J. S.; Balagopal, L. Acc. Chem. Res. 2003, 36, 899–907. (f) Dömling, A. Chem. Rev. 2006, 106, 17–89. (g) Dömling, A.; Ugi, I. Angew. Chem. 2000, 112, 3300–3344; Angew. Chem., Int. Ed. 2000, 39, 3168–3210. (h) For reviews on palladium-catalyzed insertions of isocyanides, see: (i) Heck, R. F. Palladium Reagents in Organic Synthesis; Academic Press: New York, 1985. (j) Tsuji, J. Palladium Reagents and Catalysts; John Wiley: Chichester, U.K., 1995. (k) Ito, Y.; Suginome, M. In Handbook of Organopalladium Chemistry for Organic Synthesis; Negishi, E., de Meijere, A., Eds.; Wiley: New York, 2002.

(2) For some recently reported syntheses of heterocycles from isocyanides, see: (a) Fujiwara, S.-i.; Asanuma, Y.; Shin-ike, T.; Kambe, N. J. Org. Chem. 2007, 72, 8087–8090. (b) Gilley, C. B.; Kobayashi, Y. J. Org. Chem. 2008, 73, 4198–4204. (c) St. Cyr, D. J.; Martin, N.; Arndtsen, B. A Org. Lett. 2007, 9, 449–452. (d) Winkler, J. D.; Asselin, S. M. Org. Lett. 2006, 8, 3975–3977. (e) Kanazawa, C.; Kamijo, S.; Yamamoto, Y. J. Am. Chem. Soc. 2006, 128, 10662–10663. (f) Kamijo, S.; Kanazawa, C.; Yamamoto, Y. J. Am. Chem. Soc. 2005, 127, 9260–9266. (g) Larionov, O. V.; de Meijere, A. Angew. Chem. 2005, 117, 5809–5813; Angew. Chem. Int. Ed. 2005, 44, 5664–5667.

10.1021/ol802659m CCC: \$40.75 © 2009 American Chemical Society Published on Web 12/19/2008 first exploited by Schöllkopf and Gerhart³ (Figure 1) in 1968. Since then, α -metallated isocyanides have been shown to



Figure 1. Different types of metallated isocyanides.

participate in various types of cocyclizations leading to different nitrogen-containing heterocycles.⁴ Conversely, the synthesis of indoles by the cyclization of *ortho*-methylphenyl isocyanides metallated at the benzylic position has been reported by Ito and Saegusa et al.⁵ and later was carried out

⁽³⁾ Schöllkopf, U.; Gerhart, F. Angew. Chem. 1968, 80, 842–843; Angew. Chem., Int. Ed. Engl. 1968, 7, 805–806.

⁽⁴⁾ For a review, see: (a) Schöllkopf, U. Angew. Chem. 1977, 89, 351–360; Angew. Chem., Int. Ed. Engl. 1977, 16, 339–348 and references therein.
(b) Schöllkopf, U.; Lau, H.-H.; Scheunemann, K.-H.; Blume, E.; Madawinata, K. Liebigs Ann. Chem. 1980, 4, 600–610.

employing transition metal catalysts.⁶ We envisaged that ortho-metallated phenyl isocyanides which, to our knowledge, are not known⁷ could also be versatile precursors for certain types of heterocycles.

In particular, 3H-quinazolin-4-ones, some derivatives of which occur as natural products^{8,9} (Figure 2), might be



accessible by reactions of such ortho-metallated phenyl isocyanides with isocyanates. This would be extremely useful, as *3H*-quinazolin-4-ones have been reported to possess a vast range of biological activities, including analgesic, anti-Parkinsonian, CNS depressant, and CNS stimulating as well as tranquilizing, antidepressant, and anticonvulsant effects. Some of these compounds also act as psychotropic, hypnotic, cardiotonic, and antihistamine agents^{10,11} and possess cardiovascular activity as well as antiinflammatory activity.^{10,12} Quinazolinones also inhibit monoamine oxidase, aldose reductase, tumor necrosis factor R, thymidylate synthase, pyruvic acid oxidation, as well as acetylcholine-esterase activity and are antitumor, antiulcer, antiplatelet aggregation (glycoprotein IIb/IIIa inhibitors),¹³

(5) (a) Ito, Y.; Kobayashi, K.; Saegusa, T. J. Am. Chem. Soc. **1977**, 99, 3532–3534. (b) Ito, Y.; Kobayashi, K.; Saegusa, T. J. Org. Chem. **1979**, 44, 2030–2032. (c) Ito, Y.; Kobayashi, K.; Seko, N.; Saegusa, T. Bull. Chem. Soc. Jpn. **1984**, 57, 73–84.

(6) (a) Jones, W. D.; Kosar, W. P. J. Am. Chem. Soc. **1986**, 108, 5640–5641. (b) Michelin, R. A.; Facchin, G.; Braga, D.; Sabatino, P. Organometallics **1986**, 5, 2265–2274.

(7) α -Addition of organolithium reagents to phenyl isocyanide followed by its ortho-metallation has been reported: Walborsky, H. M.; Ronman, P. J. Org. Chem. **1978**, 43, 731–734.

(8) (a) Snider, B. B.; Wu, X. Org. Lett. 2007, 9, 4913–4915. (b) Oh,
C. H.; Song, C. H. Synth. Commun. 2007, 37, 3311–3317. (c) Linder, M. R.;
Heckeroth, A. R.; Najdrowski, M.; Daugschies, A.; Schollmeyer, D.;
Miculka, C. Bioorg. Med. Chem. Lett. 2007, 17, 4140–4143. (d) Bowman,
W. R.; Elsegood, M. R. J.; Stein, T.; Weaver, G. W. Org. Biomol. Chem.
2007, 5, 103–113. (e) Duvall, J. R.; Wu, F.; Snider, B. B. J. Org. Chem.
2006, 71, 8579–8590. (f) Shim, S. H.; Kim, J. S.; Son, K. H.; Bae, K. H.;
Kang, S. S. J. Nat. Prod. 2006, 69, 400–402. (g) Jao, C.-W.; Lin, W.-C.;
Wu, Y.-T.; Wu, P.-L. J. Nat. Prod. 2008, 71, 1275–1279.

(9) For recent reviews on quinazoline alkaloids, see: (a) Michael, J. P. *Nat. Prod. Rev.* **2004**, *21*, 650–668. (b) Michael, J. P. *Nat. Prod. Rep.* **2008**, 166–187.

(10) Sinha, S.; Srivastava, M. Prog. Drug Res. 1994, 43, 143.

(11) Nagase, T.; Mizutani, T.; Ishikawa, S.; Sekino, E.; Sasaki, T.; Fujimura, T.; Ito, S.; Mitobe, Y.; Miyamoto, Y.; Yoshimoto, R.; Tanaka, T.; Ishihara, A.; Takenaga, N.; Tokita, S.; Fukami, T.; Sato, N. J. Med. Chem. **2008**, *51*, 4780–4789.

(12) de Laszlo, S. E.; Quagliato, C. S.; Greenlee, W. J.; Patchett, A. A.; Chang, R. S. L.; Lotti, V. J.; Chen, T.-B.; Scheck, S. A.; Faust, K. A.; Kivlighn, S. S.; Schorn, T. S.; Zingaro, G. J.; Siegl, P. K. S. *J. Med. Chem.* **1993**, *36*, 3207–3210.

(13) (a) Liverton, N. J.; Armstrong, D. J.; Claremon, D. A.; Remy, D. C.;
Baldwin, J. J.; Lynch, R. J.; Zhang, G.; Gould, R. J. *Bioorg. Med. Chem. Lett.* 1998, 8, 483–486. (b) Zhang, W.; Mayer, J. P.; Hall, S. E.; Weigel,
J. A. J. Comb. Chem. 2001, 3, 255–256.

(14) Gopalsamy, A.; Yang, H. J. Comb. Chem. 2000, 2, 378-381.

and hypoglycemic agents.^{10,14} They are also potent antibacterial, antifungal, antiviral, antimycobacterial, and antimalarial agents.¹⁰ Therefore, not surprisingly, they have been included in the list of molecules with "privileged structure"¹⁵ for combinatorial chemistry, capable of binding to multiple receptors with high affinity.¹⁶ Many of the numerous reported syntheses of these heterocycles start from anthranilic acid or its derivatives, but none of them use the advantages of isocyanide chemistry.^{17,18}

To investigate the possibility of generating ortho-metallated phenyl isocyanide, two possible precursors for halogen-metal exchange reactions, *ortho*-bromo- and *ortho*iodophenyl isocyanides **1** and **2a**, were synthesized. The iodo derivative **2a** turned out to undergo fast (<10 min) transmetallation reactions, when it was treated with *n*-BuLi, *t*-BuLi (-100 °C), or *i*-PrMgCl·LiCl¹⁹ (-78 °C) in THF. The target *ortho*-lithiophenyl isocyanide could also be obtained from the bromo derivative **1**, synthesized from inexpensive 2-bromoaniline. The best and most reproducible results, in this case, were achieved with *n*-BuLi in THF at -78 °C. Different electrophiles were tested in their reaction with *ortho*-lithiophenyl isocyanide generated in situ in this way (Table 1). The respective 2-substituted phenyl isocya-

| Table 1. | Synthesis | of 2-Substituted | Phenyl Isocyar | nides |
|----------|-----------|------------------|----------------|-------|
| | _ | | 2 2 | |

| electrophile | product of type 2 | yield (%) |
|----------------|----------------------------|--------------|
| l ₂ | NC 2a | 88 |
| CICO₂Me | NC 2b | 79 |
| PhSSPh | NC SPh 2c | 84 |
| MeOCHO | CHO 2d | 55 |
| | 2e O CO ₂ Me | 79 |
| СНО | OH 2f | 71 |
| , → cho | OH 2g | 80 |

nides (2) were obtained in high yields (71-88%), except for 2-formylphenyl isocyanide 2d (55%). The standard reagent for the electrophilic installation of a formyl group,

dimethyl formamide, in this case led to 2-(formylamino)benzaldehyde **6**, which presumably was formed by basecatalyzed hydrolysis of the initially formed 1,3-benzooxazine derivative **4** under the aqueous workup conditions (Scheme 1).



The 2-substituted phenyl isocyanides prepared in this way can be used for many purposes, particularly in multicomponent Ugi–Passerini reactions^{1b} or for the synthesis of correspondingly substituted anilines, to which isocyanides can easily be hydrolyzed under acidic conditions.²⁰

When isocyanates and isothiocyanates were employed as electrophiles, cyclic 3H-quinazolin-4-ones (-thiones) **8** were formed in high yields (69–91%) (Table 2).

Table 2. Synthesis of 3*H*-Quinazolin-4-ones3*H*-Quinazolin-4-thiones8



DNOV

| MINUX | | | | |
|--|--------------|-----------|-----------|--|
| R | Х | product | yield (%) | |
| Ph | 0 | 8a | 91 | |
| $4-MeC_6H_4$ | 0 | 8b | 89 | |
| $4\text{-}\mathrm{CF}_3\mathrm{C}_6\mathrm{H}_4$ | 0 | 8c | 69 | |
| $4-FC_6H_4$ | 0 | 8d | 75 | |
| $PhCH_2$ | 0 | 8e | 74 | |
| iPr | 0 | 8f | 81 | |
| cPr | 0 | 8g | 70 | |
| cPr | \mathbf{S} | 8h | 71 | |
| cHex | \mathbf{S} | 8i | 78 | |
| | | | | |

Typically, the reactions with isocyanates were carried out at -78 °C and quenched with water at the same temperature,

but in the case of isothiocyanates the mixtures were gradually warmed to -40 °C before quenching. In contrast to these reactions of a β -lithiated isocyanide, α -lithiated isocyanides



have been reported mainly to give bisadducts with isocyanates,^{4a}indicating that the metallated five-membered heterocyclic intermediates formed in that case were much

(19) (a) Krasovskiy, A.; Knochel, P. Angew. Chem. **2004**, *116*, 3396–3399; Angew. Chem., Int. Ed. **2004**, *43*, 3333–3336. (b) Ren, H.; Krasovskiy, A.; Knochel, P. Org. Lett. **2004**, *6*, 4215–4217.

(20) Schöllkopf, U.; Henneke, K.-W.; Madawinata, K.; Harms, R. Justus Liebigs Ann. Chem. 1977, 1, 40–50.

(21) (a) Murdoch, R.; Tully, W. R.; Westwood, R. J. Heterocycl. Chem.
1986, 23, 833–841. (b) Chenard, B. L.; Welch, W. M.; Blake, J. F.; Butler, T. W.; Reinhold, A.; Ewing, F. E.; Menniti, F. S.; Pagnozzi, M. J. J. Med. Chem. 2001, 44, 1710–1717. (c) Bilokin, Y. V.; Kovalenko, S. M. Heterocycl. Commun. 2000, 6, 409–414.

(22) (a) Bowman, W. R.; Elsegood, M. R. J.; Stein, T.; Weaver, G. W. *Org. Biomol. Chem.* **2007**, *5*, 103–113. (b) Tangirala, R.; Antony, S.; Agama, K.; Curran, D. P. Synlett **2005**, *18*, 2843–2846. (c) Kaneko, C.; Kasai, K.; Katagiri, N.; Chiba, T. *Chem. Pharm. Bull.* **1986**, *34*, 3672–3681.

(23) Perdicaro, A.; Granata, G.; Marrazzo, A.; Santagati, A. Synth. Commun. 2008, 38, 723-737.

⁽¹⁵⁾ Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J. J. Med. Chem. **1988**, *31*, 2235–2246.

⁽¹⁶⁾ Horton, D. A.; Bourne, G. T.; Smythe, M. L. Chem. Rev. 2003, 103, 893–930.

⁽¹⁷⁾ For reviews, see: (a) Undheim, K.; Benneche, T. *Comprehensive Heterocyclic Chemistry II*; Pergamon: Oxford, 1998; Vol. 6. (b) Connolly, D. J.; Cusack, D.; O'Sullivan, T. P.; Guiry, P. J. *Tetrahedron* **2005**, *61*, 10153–10202.

⁽¹⁸⁾ For some recently published syntheses of 3*H*-quinazolin-4-ones, see: (a) Zeghida, W.; Debray, J.; Chierici, S.; Dumy, P.; Demeunynck, M. J. Org. Chem. **2008**, 73, 2473–2475. (b) Mhaske, S. B.; Argade, N. P. J. Org. Chem. **2004**, 69, 4563–4566.

more reactive than the lithiated derivatives of type 7 formed from the β -lithiated isocyanide. This makes it possible to further diversify the 2-substituent of the 3*H*-quinazolin-4ones (-thiones) **8** by trapping the intermediate 7 with a second electrophile El²X in the same flask.

Various 2,3-disubstituted 3*H*-quinazolin-4-ones 8j-o could thus be conveniently prepared from 2-bromophenyl isocyanide 1-Br in a three-step one-pot sequence (Table 3). 2-Halo-3*H*-quinazolin-4-ones of type 8m have been reported to undergo substitution with nucleophiles²¹ and also participate in different radical cyclization processes,²² which opens access to a large variety of substituted 3*H*-quinazolin-4-ones.

Copper-catalyzed couplings of aryl thioethers of type **8k** with aryl iodides have also been reported.²³ Quenching of the lithiated intermediates of type **7** with electrophiles can

also occur intermolecularly, when the initially employed isocyanate already contains an appropriate functional group. Thus, 3-iodopropyl isocyanate and methyl 2-isocyanatobenzoate in one step gave 3*H*-quinazolin-4-ones **8n** and **8o** in 72 and 85% yield, respectively. Both deoxyvasicinone **8n**²⁴ and tryptanthrine **8o**²⁵ are naturally occurring alkaloids with important biological activities.

In conclusion, 2-substituted phenyl isocyanides are easily obtained by halogen—lithium exchange of *ortho*-bromophenyl isocyanide and subsequent trapping of the thus generated *ortho*-lithiophenyl isocyanide with electrophiles. This strategy has been effectively employed for the new three-step onepot synthesis of substituted 3*H*-quinazolin-4-ones (-thiones) including the naturally occurring alkaloids deoxyvasicinone and tryptanthrine.

Acknowledgment. This work was supported by the Land Niedersachsen. A.V.L. is indebted to the Degussa-Stiftung (Evonik Industries AG) for a graduate student fellowship.

Supporting Information Available: Experimental procedures and full characterization for all new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

OL802659M

⁽²⁴⁾ For selected examples of recent syntheses of deoxyvasicinone, see: (a) Mhaske, S. B.; Argade, N. P. *J. Org. Chem.* **2001**, *66*, 9038–9040. (b) Liu, J.-F.; Ye, P.; Sprague, K.; Sargent, K.; Yohannes, D.; Baldino, C. M.; Wilson, C. J.; Ng, S.-C. *Org. Lett.* **2005**, *7*, 3363–3366. (c) Lee, E. S.; Park, J.-G.; Jahng, Y. *Tetrahedron Lett.* **2003**, *44*, 1883–1886. (d) Hamid, A.; Elomri, A.; Daich, A. *Tetrahedron Lett.* **2006**, *47*, 1777–1781. (e) Bowman, W. R.; Elsegood, M. R. J.; Stein, T.; Weaver, G. W. *Org. Biomol. Chem.* **2007**, *5*, 103–113.

⁽²⁵⁾ For recent syntheses of tryptanthrine, see: (a) Jahng, K. C.; Kim, S. I.; Kim, D. H.; Seo, C. S.; Son, J.-K.; Lee, S. H.; Lee, E. S.; Jahng, Y. *Chem. Pharm. Bull.* **2008**, *56*, 607–609. (b) Batanero, B.; Barba, F. *Tetrahedron Lett.* **2006**, *47*, 8201–8203. (c) See also: ref 21a.